Connect with us

Finance

Big Tech AI investment is going right to Nvidia: Chart of the Week

Published

on

Big Tech AI investment is going right to Nvidia: Chart of the Week

This is The Takeaway from today’s Morning Brief, which you can sign up to receive in your inbox every morning along with:

Throughout this earnings season, investors have been especially focused on Big Tech’s capital expenditures.

This spending is seen as a barometer for how bullish Microsoft, Amazon, Meta, and Alphabet are about what AI will do for them. Though, as Julie Hyman wrote Thursday, it’s a little more complicated than that, since they must go all in to even get a seat at the table.

But the nature of supply chain dynamics means that what gathers and melts in the mountains pours into the rivers and lakes.

And as our Chart of the Week shows, Big Tech is still making it rain. And Nvidia is the lake.

Advertisement

According to estimates from Bloomberg, coupled with quarterly reports, more than 40% of Nvidia’s revenue comes from some familiar names among the “Magnificent Seven” stocks — Microsoft, Meta, Alphabet, and Amazon.

The biggest transfer is from Microsoft, with spending from the world’s most valuable company accounting for 19% of Nvidia’s revenue. This makes the company its biggest customer by far, nearly doubling Meta’s spend and tripling that of Alphabet and Amazon.

And on the Microsoft side, Bloomberg’s data shows Nvidia accounts for 45% of its capital expenditures, whereas the chipmaker only gets 15% of Alphabet’s outlays, for example.

In the AI jungle, this data is a reminder that the chipmakers eat first, long before the hyperscalers can offer much more than hints to investors about when the AI investments will turn into AI revenue streams.

Still, this is one of the key charts that have helped power the market, especially through the tech earnings season.

Advertisement

For now, the lack of revenue isn’t too worrying to investors — though doubts are rising! — as it’s still hard to imagine the trillion-dollar Microsoft doesn’t know something they don’t about the opportunity.

Ethan Wolff-Mann is a Senior Editor at Yahoo Finance, running newsletters. Follow him on X @ewolffmann.

Click here for the latest technology news that will impact the stock market

Read the latest financial and business news from Yahoo Finance

morning brief image

morning brief image

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Finance

Private equity firm will finance Harvard research lab, in possible template for future

Published

on

Private equity firm will finance Harvard research lab, in possible template for future

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.

A private equity firm has stepped in to finance a biological research lab at Harvard University, administrators said Monday, while also launching a biotech alongside it that will develop new therapies for metabolic conditions.

As Harvard grapples with severe financing cuts undertaken by the Trump administration, some university officials believe the unusual arrangement could be at least one model to fund other academic research in the future.

Under the deal announced Monday, İş Private Equity, a Turkish firm, has committed $39 million to a laboratory run by Gökhan Hotamışlıgil, a professor of genetics and metabolism at the T.H. Chan School of Public Health. The firm, which is a branch of Turkey’s İşbank Group, also plans to invest an undisclosed amount of money in any drug candidates that come out of Hotamışlıgil’s laboratory and are moved into a new biotech called Enlila. 

It’s a relatively modest deal, in the scope of investment banking. But the collaboration provides much-needed capital at a time when the model for funding scientific research has been thrown into chaos. 

Advertisement

STAT+ Exclusive Story

Advertisement

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

Advertisement

To read the rest of this story subscribe to STAT+.

Subscribe

Advertisement
Continue Reading

Finance

Kinatico Ltd’s (ASX:KYP) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Published

on

Kinatico Ltd’s (ASX:KYP) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Kinatico (ASX:KYP) has had a rough month with its share price down 7.7%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean that the stock could potentially rise in the long-term given how markets usually reward more resilient long-term fundamentals. Specifically, we decided to study Kinatico’s ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder’s equity.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

Advertisement

So, based on the above formula, the ROE for Kinatico is:

3.2% = AU$840k ÷ AU$26m (Based on the trailing twelve months to December 2024).

The ‘return’ is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each A$1 of shareholders’ capital it has, the company made A$0.03 in profit.

See our latest analysis for Kinatico

So far, we’ve learned that ROE is a measure of a company’s profitability. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don’t necessarily bear these characteristics.

Advertisement

It is hard to argue that Kinatico’s ROE is much good in and of itself. Not just that, even compared to the industry average of 5.0%, the company’s ROE is entirely unremarkable. Despite this, surprisingly, Kinatico saw an exceptional 44% net income growth over the past five years. We reckon that there could be other factors at play here. Such as – high earnings retention or an efficient management in place.

Next, on comparing with the industry net income growth, we found that Kinatico’s growth is quite high when compared to the industry average growth of 24% in the same period, which is great to see.

Continue Reading

Finance

Mutuum Finance Short-Term Price Forecast: Will It Be The Next Crypto To Hit $1?

Published

on

Mutuum Finance Short-Term Price Forecast: Will It Be The Next Crypto To Hit ?
Mutuum Finance Short-Term Price Forecast reveals a surging altcoin capturing investor attention in the crypto market. Mutuum Finance (MUTM) is soaring through phase 5 of its 11-phase presale, raising $10,550,000 and selling over 550 million tokens to 12,000 holders. Priced at $0.03, the token has tripled from its opening phase at $0.01, signaling r…
Continue Reading
Advertisement

Trending